B. Riley Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)

Key Points

• B. Riley has initiated coverage on Theravance Biopharma (NASDAQ:TBPH) with a buy rating and a price target of $28.00, suggesting a potential upside of 104.38% from the previous close.
• Additionally, other analysts, including Zacks Research and BTIG, have upgraded the stock ratings, with the average target now at $23.00, and a majority of ratings being buy or strong-buy.
• Insider trading activity showed that SVP Rhonda Farnum sold 10,000 shares at an average price of $11.39, while institutional investors have significantly increased their stakes in the company.

Investment analysts at B. Riley started coverage on shares of Theravance Biopharma (NASDAQ:TBPH - Get Free Report) in a note issued to investors on Friday, Marketbeat.com reports. The brokerage set a "buy" rating and a $28.00 price target on the biopharmaceutical company's stock. B. Riley's price objective would indicate a potential upside of 104.38% from the company's previous close.

Other equities research analysts have also issued reports about the company. Zacks Research raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Friday, August 15th. BTIG Research boosted their price target on Theravance Biopharma from $24.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, June 27th. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 16th. Finally, Jones Trading raised Theravance Biopharma to a "strong-buy" rating and set a $24.00 price target for the company in a research report on Tuesday, June 17th. Two analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $23.00.

Theravance Biopharma Stock Up 0.4%

Shares of NASDAQ TBPH opened at $13.70 on Friday. The business has a fifty day simple moving average of $12.33 and a two-hundred day simple moving average of $10.56. The firm has a market cap of $689.93 million, a PE ratio of 57.08 and a beta of 0.05. Theravance Biopharma has a twelve month low of $7.88 and a twelve month high of $14.55.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 10,000 shares of the business's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $11.39, for a total transaction of $113,900.00. Following the transaction, the senior vice president directly owned 326,918 shares in the company, valued at $3,723,596.02. The trade was a 2.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 6.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. GAMMA Investing LLC grew its stake in Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 3,281 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in Theravance Biopharma by 18.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company's stock worth $55,000 after buying an additional 781 shares during the last quarter. AQR Capital Management LLC purchased a new position in Theravance Biopharma during the 1st quarter worth $101,000. R Squared Ltd grew its stake in Theravance Biopharma by 636.6% during the 1st quarter. R Squared Ltd now owns 12,522 shares of the biopharmaceutical company's stock worth $112,000 after buying an additional 10,822 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Theravance Biopharma during the 4th quarter valued at about $119,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.